| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Salivary Gland Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Salivary Gland Diseases | |||||
| Salivary Gland Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Head and Neck Neoplasms | |||||
| Mouth Diseases | |||||
| Mouth Neoplasms | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Stomatognathic Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| ZD1839 (Iressa) | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Gefitinib | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Protein Kinase Inhibitors | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| M.D. Anderson Cancer Center | |||||
| AstraZeneca | |||||
|
